RSV‐associated hospitalization in adults in the USA: A retrospective chart review investigating burden, management strategies, and outcomes
Open Access
- 14 April 2022
- journal article
- review article
- Published by Wiley in Health Science Reports
- Vol. 5 (3) , e556
Abstract
Background and Aims: The burden of respiratory syncytial virus (RSV) infection in adults is of growing concern. This study was designed to quantify disease burden, treatment approaches, and outcomes associated with RSV infections in adult subpopulations, from prehospitalization to hospital discharge.Methods: A retrospective chart analysis was conducted to collect patient‐case data from hospitalized US adults (aged >18 years) with RSV infection during two RSV seasons. Patients were categorized into risk groups: comorbid lung disease, immunocompromised, older adults (aged ≥65 years), and other adults (aged <65 years). Physicians reported diagnosis, treatment choices including respiratory supportive therapy (oxygen and fluid supplementation), and outcome variables using a standardized online case form.Results: The majority (277/379; 73%) of patients presented to the emergency room, with a mean age of 60 years. Once hospitalized, the median length of stay was 6.0 days (3.0–9.0), with disease severity having the greatest impact on duration of stay. No significant between‐group differences in rates of patients requiring management in intensive care units were found (comorbid lung disease, 28%; immunocompromised, 36%; older adults, 26%; and other adults, 23%). Overall, respiratory supportive therapy was the most commonly used form of treatment. Antibiotics were administered in over half of all risk groups (comorbid lung disease, 61%; immunocompromised, 59%; older adults, 59%; and other adults, 51%). Patients usually required follow‐up visits following discharge, with 10%–16% requiring skilled nursing care and approximately 25% requiring assistance from a social worker.Conclusion: RSV in adult subpopulations, irrespective of age, is a significant burden to healthcare systems.Keywords
Funding Information
- Janssen Pharmaceutica
This publication has 25 references indexed in Scilit:
- Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort studyBMC Infectious Diseases, 2014
- Estimates of mortality attributable to influenza and RSV in the United States during 1997–2009 by influenza type or subtype, age, cause of death, and risk statusInfluenza and Other Respiratory Viruses, 2014
- Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Factors Determining Progression to Lower Respiratory Tract DiseaseThe Journal of Infectious Diseases, 2013
- High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus InfectionsClinical Infectious Diseases, 2013
- Mortality Attributable to 9 Common Infections: Significant Effect of Influenza A, Respiratory Syncytial Virus, Influenza B, Norovirus, and Parainfluenza in Elderly PersonsThe Journal of Infectious Diseases, 2012
- Rates of Hospitalizations for Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza Virus in Older AdultsThe Journal of Infectious Diseases, 2012
- Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008Clinical Infectious Diseases, 2012
- Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial VirusClinical Infectious Diseases, 2010
- Respiratory Syncytial Virus Infection in Elderly and High-Risk AdultsNew England Journal of Medicine, 2005
- Respiratory Syncytial Virus Infection in AdultsClinical Microbiology Reviews, 2000